David Rawitscher, MD
Cardiovascular Disease · Plano, TXNPI 1700873247
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,393 of the $122,249 with a category attached, or 66.6%. It is spread thinly across 48 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2019 at $49,261 and has fallen 61.3% since, to $19,057 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $182.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$26K
- Johnson & Johnson$25K
- Itamar Medical Inc$14K
- E.r. Squibb & Sons, L.L.C.$13K
- Bayer$12K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
- plus $21K from 42 others
Across 11 payments — averaging $19,229 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$193K
- Amgen$19K
What the payments were for
- Consulting fees$10,2008%
- Speaking & faculty fees$81,39367%
- Travel & lodging$5,0624%
- Food & beverage$20,78917%
- Education$4,7684%
- Entertainment$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$25,526
- XARELTO$24,139
- Kerendia$11,569
- WatchPATONE$11,069
- LifeVest$10,500
- CAMZYOS$9,164
- WatchPat$3,239
- ENTRESTO$2,827
- CARDIOMEMS$1,441
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,371
- Impella$577
- Inspire$238
- HeartMate 3 Left Ventricular Assist Device$145
- HeartMate$144
- LifeSPARC System$140
- MULTAQ$125
- AMVUTTRA$123
- ONPATTRO$122
- ORENITRAM$112
- TYVASO$112
How this compares
$122,249 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 58 | $1,653,057 |
| EliquisApixaban | 481 | $625,183 |
| JardianceEmpagliflozin | 396 | $434,952 |
| EntrestoSacubitril/Valsartan | 237 | $352,184 |
| XareltoRivaroxaban | 235 | $300,748 |
| Repatha SureclickEvolocumab | 155 | $194,937 |
| FarxigaDapagliflozin Propanediol | 169 | $180,478 |
| VascepaIcosapent Ethyl | 69 | $67,892 |
| MultaqDronedarone Hcl | 21 | $30,176 |
| Praluent PenAlirocumab | 24 | $23,362 |
| BrilintaTicagrelor | 21 | $20,564 |
| Rosuvastatin Calcium | 1,178 | $18,018 |
| Ezetimibe | 550 | $15,771 |
| Icosapent Ethyl | 35 | $14,205 |
| Metoprolol Succinate | 848 | $14,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,167 | $2,278,241539 claims |
| Boehringer IngelheimJardiance | $428 | $434,952396 claims |
| NovartisEntresto | $7,585 | $352,184237 claims |
| Johnson & JohnsonXarelto | $24,844 | $300,748235 claims |
| AstraZenecaFarxiga, Brilinta | $581 | $201,042190 claims |
| Sanofi-aventis U.S. LLCMultaq | $84 | $30,17621 claims |
| Esperion Therapeutics, Inc.Nexletol | $50 | $11,59411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- Sahil BakshiPlano$167K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.